Pentz R.D.,Emory University |
Harvey R.D.,Emory University |
Farmer Z.L.,University of Alabama at Birmingham |
Liu Y.,Emory University |
And 4 more authors.
Cancer | Year: 2012
BACKGROUND: Ethical concerns about phase 1 trials persist. Important conceptual advances have been made in understanding concepts used to describe misunderstanding. However, a systematic, empirical evaluation of the frequency of misunderstanding incorporating recent developments is lacking. METHODS: The authors queried 95 participants in phase 1 trials to provide a more sophisticated estimate of the proportion who had therapeutic misconception (TM), defined as misunderstanding the research purpose or how research differs from individualized care, and therapeutic misestimation (TMis), defined as incorrectly estimating the chance of a research trial benefit as >20% or underestimating risk as 0%. RESULTS: Sixty-five of 95 respondents (68.4%) had TM, which was associated in a multivariate analysis with lower education and family income (P =.008 and P =.001, respectively), but TM was not associated with the vulnerability of having hardly any treatment options. Eighty-nine of 95 respondents (94%) had TMis, although only 18% reported this was a factual estimate. Although the risks of investigational agents and those exacerbated by research, such as uncertain outcomes, were mentioned (39% and 41% of respondents, respectively), risks novel to research, such as research biopsies, were rarely mentioned (3% of respondents). Although most of these respondents believed that their chance of benefit was greater and that their risk was lower than the population chance (optimists) (54.6%), a substantial minority of respondents (37.6%) were pessimists. CONCLUSIONS: TM continues to be prevalent. Estimates of personal benefit were not usually meant to report facts, it remains unknown whether respondents in the current study had TMis. Although they are not more vulnerable, phase 1 participants need improved understanding of key TM concepts, with attention to risks that are not present in standard of care. Cancer 2012. © 2012 American Cancer Society.
News Article | November 30, 2016
ATLANTA, GA / ACCESSWIRE / November 30, 2016 / LifeSource Health, Inc. a Syracuse New York based company is pleased to announce the addition of Dee Cantrell, RN, BSN, MS, FHIMSS, CIO to their executive management team. Dee has 35 years of healthcare experience with 24 in health information technology, strategy and operations and recently retired from Emory Healthcare where she served as CIO for the last 16 years. She is the only professional to be named Georgia CIO of the Year - twice. Dee has worked with major academic institutions, not-for-profit healthcare delivery systems, community providers, large physician practices, managed care organizations as well as federal and state agencies. She has served in a key leadership role for the strategic plan, technology implementation and sustainment of the state wide Health Information Exchange (HIE) for Georgia, as chair of the Technology Committee and as member of the Board of Directors for the Georgia Health Information Network (GaHIN). Additionally, she is the President of the Georgia Chapter of Health Information management Systems Society (HIMSS). "We couldn't be more pleased to bring someone the caliber of Dee Cantrell to our team. Dee brings significant healthcare knowledge and leadership and will oversee the promotion and rollout of LifeSource's mobile platform "AtTheScene™" - a real-time mobile application designed to provide first responders with vital health information when the patient is most critical," said Timothy Kelly, LifeSource Founder and CEO. Dee Cantrell adds, "When you realize that medical misinformation errors lead to over 240,000 deaths and hundreds of millions of dollars in unnecessary spending each year it's comforting to know that LifeSource's AtTheScene mobile platform can significantly increase the speed and quality of care and save lives in the process." About LifeSource Health, Inc.: LifeSource Health, Inc., is healthcare software company that delivers electronic patient data solutions for EMS and first responders. The company has offices in Syracuse, NY and Marietta, GA. Please visit lifesourcehealthinc.com for more information.
News Article | October 28, 2016
SmartCare Urgent Care, an urgent care and primary care provider operating six clinical sites in Atlanta and Athens, is affiliating with the Emory Healthcare Network, Emory Healthcare’s clinically integrated network of more than 2,000 employed and private practice physicians. This partnership enhances Emory Healthcare’s geographical reach and provides the network with ability to offer convenient, compassionate, on-demand care for non-life threatening health concerns. As part of the Emory Healthcare Network, SmartCare Urgent Care will be able to link into Emory Healthcare’s electronic medical record system to provide seamless care and transition for patients. If needed, patients who are referred to specialists within the Emory Healthcare Network for more complex treatment will already have a health record in the system. SmartCare Urgent Care offers patients an exceptional customer experience efficiently with modern, upscale amenities such as an advanced queuing system that allows customers to choose and hold an appointment time that is convenient for them. “SmartCare Urgent Care is delighted to affiliate with Emory Healthcare and pair our strengths to maintain the health and wellness of all those we serve,” says Kavita Kotte, MD, co-founder and Chief Medical Officer of SmartCare Urgent Care. “This clinical affiliation broadens our ability to afford our patients easy access to Emory specialists and streamline their continuity of care when necessary.” SmartCare Urgent Care offers an array of medical services to patients whether those services are needed on-demand or through scheduled appointments. “Our centers offer patients access to advanced care for any serious, non-life threatening emergency. We treat all injuries, illnesses, and time-sensitive ailments and have on-site x-ray and lab capabilities,” says Zobair Nagamia, MD, Chief Operating Officer of SmartCare Urgent Care. SmartCare Urgent Care serves nearly 75,000 patients annually and will continue to expand its existing footprint with additional sites in active development. SmartCare Urgent Care is physician owned and operated. At SmartCare, we are committed to placing the needs of our patients first by providing the highest standard of illness, injury and wellness care. No appointments are necessary at our modern, state of the art facilities in Atlanta Metro and surrounding areas, where we create a comfortable and convenient alternative to traditional emergency room and doctor’s office. SmartCare offers extended hours and courteous, experienced staff to get you on your way to feeling better fast. Above All, our mission is to provide you with “affordable care at your convenience”. To learn more about us, please visit our website at http://www.smartcareuc.com. Emory Healthcare, with almost 16,000 employees, is the most comprehensive health system in Georgia. In fiscal year 2015, Emory Healthcare had $2.8 billion in annual net revenue and provided $67.4 million in charity care. System-wide, it has 1,958 licensed patient beds. Emory Healthcare is the only health system in Georgia with three Magnet-designated hospitals, Emory Saint Joseph's Hospital, Emory University Hospital and Emory University Orthopaedics & Spine Hospital, for nursing excellence. Emory Healthcare's core purpose: "To serve humanity by improving health through integration of education, discovery and health care." For more information, visit http://www.emoryhealthcare.org.
Davis C.C.,Emory Healthcare |
Shah K.S.,Emory Healthcare |
Lechowicz M.J.,Emory University
Current Oncology Reports | Year: 2015
Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatment of the rare disease idiopathic multicentric Castleman’s disease (MCD). MCD is a non-clonal lymphoproliferative disorder in which common symptoms include fever, night sweats, weight loss, and fatigue. Symptoms are driven by an overall hypercytokinemia, predominantly IL-6. While under clinical development, siltuximab was studied in several other disease states including multiple myeloma, non-Hodgkin lymphomas, and several solid tumors in which it did not demonstrate significant benefit. The efficacy of siltuximab in MCD is mainly confined to systemic symptomatic response and quality of life benefits with minimal complete responses and approximately 30 % partial responses, by radiographic criteria. Siltuximab treatment therefore is important in the overall treatment of this rare disease state. This review focuses on the clinical development and pharmaceutical approval of siltuximab. © 2015, Springer Science+Business Media New York.
Distribution of pathogens in central line-associated bloodstream infections among patients with and without neutropenia following chemotherapy: Evidence for a proposed modification to the current surveillance definition
Steinberg J.P.,Emory University |
Robichaux C.,Emory Healthcare |
Tejedor S.C.,Emory University |
Reyes M.D.,Emory University |
Jacob J.T.,Emory University
Infection Control and Hospital Epidemiology | Year: 2013
objective. Many bloodstream infections (BSIs) occurring in patients with febrile neutropenia following cytotoxic chemotherapy are due to translocation of intestinal microbiota. However, these infections meet the National Healthcare Safety Network (NHSN) definition of central line-associated BSIs (CLABSIs). We sought to determine the differences in the microbiology of NHSN-defined CLABSIs in patients with and without neutropenia and, using these data, to propose a modification of the CLABSI definition. design. Retrospective review. setting. Two large university hospitals over 18 months. methods. All hospital-acquired BSIs occurring in patients with central venous catheters in place were classified using the NHSN CLABSI definition. Patients with postchemotherapy neutropenia (500 neutrophils/mm3 or lower) at the time of blood culture were considered neutropenic. Pathogens overrepresented in the neutropenic group were identified to inform development of a modified CLABSI definition. results. Organisms that were more commonly observed in the neutropenic group compared with the nonneutropenic group included Escherichia coli (22.7% vs 2.5%; P<.001) but not other Enterobacteriaceae, Enterococcus faecium (18.2% vs 6.1%; P =.002), and streptococci (18.2% vs 0%; P<.001). Application of a modified CLABSI definition (removing BSI with enterococci, streptococci, or E. coli) excluded 33 of 66 neutropenic CLABSIs and decreased the CLABSI rate in one study hospital with large transplant and oncology populations from 2.12 to 1.79 cases per 1,000 line-days. conclusions. Common gastrointestinal organisms were more common in the neutropenia group, suggesting that many BSIs meeting the NHSN criteria for CLABSI in the setting of neutropenia may represent translocation of gut organisms. These findings support modification of the NHSN CLABSI definition. © 2012 by The Society for Healthcare Epidemiology of America. All rights reserved.
Copland I.B.,Emory University |
Garcia M.A.,Emory Healthcare |
Waller E.K.,Emory University |
Roback J.D.,Emory University |
Galipeau J.,Emory University
Biomaterials | Year: 2013
Human platelet lysate (PL) represents an attractive alternative to fetal bovine serum (FBS) for the exvivo expansion of human mesenchymal stromal cells (MSCs). However, there is controversy whether MSCs propagated in unfractionated PL retain their immunosuppressive properties. Since fibrinogen can be a major component of PL, we hypothesized that the fibrinogen content in PL negatively affects the suppressor function of MSCs. Pools of outdated plateletpheresis products underwent a double freeze-thaw centrifugation and filtration to produce unfractionated platelet lysates (uPL), followed by a temperature controlled clotting procedure to produce a fibrinogen depleted platelet lysate (fdPL). Fibrinogen depletion affected neither the mitogenic properties of PL or growth factor content, however fdPL was less prone to develop precipitate over time. Functionally, fibrinogen interacted directly with MSCs, dose dependently increased IL-6, IL-8 and MCP-1 protein production, and compromised the ability of MSCs to up-regulate indoleamine dioxygenase (IDO), as well as, mitigate T-cell proliferation. Similarly uPL expanded MSCs showed a reduced capability of inducing IDO and suppressing T-cell proliferation compared to FBS expanded MSCs. Replacing uPL with fdPL largely restored the immune modulating effects of MSCs. Together these data suggest that fibrinogen negatively affects the immunomodulatory functions of MSCs and fdPL can serve as non-xenogenic mitogenic supplement for expansion of clinical grade MSCs for immune modulation. © 2013 Elsevier Ltd.
Demma L.J.,Emory University |
Paciullo C.A.,Emory Healthcare |
Levy J.H.,Emory University
Journal of Thoracic and Cardiovascular Surgery | Year: 2012
Objective: Patients recovering from cardiothoracic surgery are known to be at increased risk of heparin-induced thrombocytopenia. Postoperatively, if heparin-induced thrombocytopenia is suspected, heparin is discontinued immediately and an alternative anticoagulant, such as the direct thrombin inhibitor argatroban, is administered. Current data regarding the safety and efficacy of argatroban in the postoperative cardiothoracic surgical patient in the intensive care setting are limited. Methods: Data were collected retrospectively from January 1, 2007, to December 31, 2010, from patients tested for antiplatelet factor 4/heparin antibodies on clinical suspicion of heparin-induced thrombocytopenia after cardiothoracic surgery. We evaluated the use of argatroban as a therapeutic agent for the postoperative treatment of suspected heparin-induced thrombocytopenia by comparing thrombotic and bleeding events, platelet dynamics, antiplatelet factor 4/heparin antibody titer, and clinical probability score between patients who did and did not receive argatroban. Results: Eighty-seven patients were included; 47 patients (54%) were treated with argatroban, and 40 patients (46%) were not treated with argatroban. There was no association between argatroban therapy and bleeding, mortality, length of stay, or pretreatment thrombotic events. Among all patients, antiplatelet factor 4/heparin antibody titer and clinical probability score were higher in patients treated with argatroban. Conclusions: Clinical suspicion of heparin-induced thrombocytopenia as detected by clinical probability score and thrombotic complications should prompt immediate cessation of heparin and initiation of an alternative anticoagulant such as argatroban. The results from this study demonstrate that argatroban should be considered without increased risk for adverse events, including bleeding, in the cardiothoracic intensive care unit after surgery. Copyright © 2012 by The American Association for Thoracic Surgery.
Teagarden D.L.,Emory Healthcare |
Meador K.J.,Stanford University |
Loring D.W.,Emory University
Epilepsy Research | Year: 2014
Purpose: Vitamin D is important for bone health, and vitamin D deficiency may contribute to other disorders (e.g., autoimmune, infections, cancer, degenerative, diabetic, and vascular). Enzyme-inducing antiepileptic drugs have been particularly implicated for osteoporosis risk given their effects on vitamin D. We examined the prevalence of vitamin D deficiency in adult epilepsy patients. Methods: We conducted an observational study of consecutive epilepsy patients treated by two clinicians at the Emory University Epilepsy Center from 2008 to 2011 in order to determine the frequency of low vitamin D levels and possible differential antiepileptic drug risks. Vitamin D 25-OH levels were categorized as low (<20. ng/ml), borderline (20-29. ng/ml), or normal (≥30. ng/ml). Antiepileptic drugs were categorized based on their enzyme inducing properties. Descriptive and inferential statistics were employed. Results: Vitamin D levels were obtained on 596 patients with epilepsy. Mean age was 41 years (SD = 14; range = 18-81); 56% were women. Race/ethnicity was 55% Caucasian, 34% Black, 2% Asian, and 7% Unknown. The mean vitamin D level was 22.5 (SD = 11.9; range = <4 to 98), and 45% had level <20. ng/ml. Mean vitamin D levels ( F = 6.48, p = .002) and frequencies of vitamin D categories ( p = .002, Chi square test) differed across the antiepileptic drug groups. Vitamin D deficiency was present in 54% of enzyme-inducing and 37% of non-enzyme-inducing antiepileptic drugs groups. Conclusions: Vitamin D deficiency is common in patients with epilepsy on antiepileptic drugs. Monitoring of vitamin D should be considered as part of the routine management of patients with epilepsy. © 2014 Elsevier B.V.
News Article | December 21, 2016
SAN FRANCISCO--(BUSINESS WIRE)--Fitbit, Inc. (NYSE:FIT), the leader in the connected health and fitness market, announced the addition of new customers including New York Life, Pitney Bowes, SAP, Sharp Healthcare and partners that will offer Fitbit activity trackers and programs to employees across a variety of industries. Fitbit continues to build corporate wellness programs that prioritize increasing employee engagement, improving health outcomes and lowering healthcare costs. Data from ABI Research suggests that corporate wellness programs that include wearable devices increase participation from an average of 20 percent without wearables to 60 percent or higher with wearables, with some employers reporting participation rates above 90 percent1. According to a 2016 report by IBISWorld, companies are seeking partners that can keep up with the latest trends in software and technology.2 “Employers continue to look to consumer-oriented technology and services to develop wellness programs that can empower people to take charge of their health and fitness,” said Amy McDonough, Vice President and General Manager of Fitbit Group Health. “Fitbit’s corporate wellness offering is built around the understanding that better, people-oriented technology enables stronger results using wearable devices that consumers love.” Customer wins spanning across industries including healthcare, financial services, consumer goods, higher education, technology and insurance highlight the continued investment organizations are making in the health and wellbeing of their workforce. Companies including Keck Medicine of the University of Southern California (USC), New York Life, Pitney Bowes, SAP, Sharp Healthcare and Teach for America will now be working with Fitbit Group Health to develop programs tailored to the needs of their unique employee populations. “With a large workforce across a variety of job functions and locations we needed a wellness solution that would be effective for a diverse population,” said, Megan Spurling, Manager of Employee Wellness at Sharp Healthcare. “The engagement of the Fitbit brand across consumers was a big factor in selecting Fitbit as our wellness partner to help ensure greater success of our initiatives in this area.” Knowing that one size does not fit all in health and fitness, Fitbit designs devices and programs to integrate seamlessly into people’s daily lives and activities. Fitbit data suggests that users with friends on the Fitbit platform take an average of 11 percent more steps than users without a friend on the platform and employer wellness customers are taking advantage of this trend to engage beyond just the employee. Many Fitbit customers utilize friends and family discounts as a part of their wellness program, including Pitney Bowes, Emory University and Emory Healthcare and the University of Kentucky. SAP, the leader in business applications, launched their program by offering a subsidized Fitbit for their employees and additional discounted devices to friends and family. Due to the popularity of the 2016 program, Fitbit will expand access to SAP global employees in 2017. Pitney Bowes is taking a similar approach, offering subsidized devices for 10,000 employees and their spouses and domestic partners in the U.S. and discounts to the other employees worldwide. Those that participate will have the added convenience of automatically syncing their fitness and nutrition data while participating in company-provided wellness programs, open to employees and family members. “We know that staying healthy and moving more throughout the work day can be challenging,” said Andrew Gold, Vice President of Total Rewards at Pitney Bowes. “By offering Fitbit to our employees, we’re helping to motivate people at Pitney Bowes to take healthy actions while having fun with their family, friends and co-workers.” Fitbit has also announced a strategic partnership with leading wellness provider Virgin Pulse, expanding access to Fitbit’s technology and services to their customers. Fitbit and Virgin Pulse launched a strategic partnership, in which the companies will offer preferred pricing on Fitbit trackers and collaborate to develop unique user experiences for the more than 2,200 Virgin Pulse employer customers around the world. Fitbit Group Health corporate wellness offering includes access to Fitbit’s suite of award winning trackers, custom e-commerce storefronts, seamless distribution, engaging wellness challenges and comprehensive tracking and reporting. Fitbit Group Health corporate wellness solutions are available direct to employer or in partnership with other corporate wellness partners. For more information about Fitbit Group Health’s corporate wellness offering, visit www.fitbit.com/group-health. Fitbit helps people lead healthier, more active lives by empowering them with data, inspiration and guidance to reach their goals. As the leader in the connected health and fitness category, Fitbit designs products and experiences that track everyday health and fitness. Fitbit’s diverse line of award-winning products includes Fitbit Surge®, Fitbit Blaze™, Fitbit Charge 2™, Fitbit Charge HR™, Alta™, Fitbit Charge™, Fitbit Flex 2™, Fitbit Flex®, Fitbit One® and Fitbit Zip® activity trackers, as well as the Aria® Wi-Fi Smart Scale. Fitbit products are carried in 54,000 retail stores and in 65 countries around the globe. Fitbit Group Health uses the power of the Fitbit activity trackers, software, and services to deliver innovative solutions for corporate wellness, weight management, insurance and clinical research. Fitbit and the Fitbit logo are trademarks or registered trademarks of Fitbit, Inc. in the US and other countries. Additional Fitbit trademarks can be found at www.fitbit.com/legal/trademark-list. Third-party trademarks are the property of their respective owners. 2 Citation: IBISWorld Industry Report OD4621 Corporate Wellness Services in the US, February 2016 http://static.politico.com/3e/68/b29a1ff04e7d8bc7c8231352ffc5/ibis-study-on-corporate-wellness-programs.pdf
News Article | February 17, 2017
Clarkston area will provide opportunities for both moving and junk removal operations to quickly build a solid customer base CLARKSTON, GA--(Marketwired - February 17, 2017) - College Hunks Hauling Junk and Moving -- which has been featured on "Blue Collar Millionaire," "Shark Tank," and other primetime shows -- has expanded into Clarkston. The company provides local moving, junk removal, donation pickups, general labor and more. Bill Castle will lead the Hunks team (Hunks stands for Honest, Uniformed, Nice, Knowledgeable Service). Before College Hunks, he worked at Emory University for 26 years. Some of the roles he held included Director, Facilities Management, and positions within Emory Healthcare. The Clarkston College Hunks franchise is located at 3550 Clarkston Industrial Blvd, Ste E and will serve customers throughout DeKalb County. The franchise is set to open for business on February 20, 2017. Castle is excited about getting his business up and running in Clarkston, Georgia. "Clarkston is one of Georgia's destination cities for world refugees. It has built a very close knit community of diverse members because of this conscious decision to welcome these families. I want to be a part of that and participate in employing these families," said Castle. The structure support, core values, repurposing unwanted items and the helpful staff is what attracted Castle to College Hunks. The College Hunks core values are Building Leaders; Create a Fun, Enthusiastic Team Environment; Listen, Fulfill & Delight; and Always Branding. Castle's favorite core value is building leaders. "My most meaningful moments were times in my career when I had the opportunity to build successful teams and grow leaders," said Castle. The desire to mentor leaders and aggressively grow a new market is why College Hunks Hauling Junk and Moving awarded Castle the rights to the franchise in Clarkston. "We are very aggressive when it comes to growth, but we want to do it the right way," said College Hunks Hauling Junk President and Co-Founder, Nick Friedman. "That means, first and foremost, finding the right franchise partner. We only want to work with people who are enthusiastic about what we've built as a company, and who believe in our mantra of 'Move the World.' Bill and his team live and breathe our core values, and clients are going to be blown away by the level of service they receive." College Hunks Hauling Junk and Moving in Clarkston is open from 8 a.m. to 9 p.m. Monday through Saturday, or from 9 a.m. to 6 p.m. on Sunday. You can reach them at (404) 592-5219 or https://collegehunkshaulingjunk.com/locations/ga/clarkston/ To learn about owning a College Hunks Hauling Junk and Moving franchise, visit www.collegehunksfranchise.com. To learn about owning a College Hunks Hauling Junk and Moving franchise, visit www.collegehunksfranchise.com.